Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 377

1.

Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.

Bard JM, Lassalle R, Capeau J, Bach-Ngohou K, Nazih-Sanderson F, Rémy G, Reynes J, Ecobichon JL, Savès M, Raffi F; Aproco-Copilote Study Group.

Antivir Ther. 2006;11(3):361-70.

PMID:
16759053
2.
3.

Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.

Rimland D, Guest JL, Hernández I, Del Rio C, Le NA, Brown WV.

HIV Med. 2005 Sep;6(5):326-33.

4.

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy.

Vigouroux C, Maachi M, Nguyên TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP.

AIDS. 2003 Jul 4;17(10):1503-11.

PMID:
12824788
5.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062
6.

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients.

Fauvel J, Bonnet E, Ruidavets JB, Ferrières J, Toffoletti A, Massip P, Chap H, Perret B.

AIDS. 2001 Dec 7;15(18):2397-406.

PMID:
11740190
8.

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.

Negredo E, Ribalta J, Paredes R, Ferré R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B.

AIDS. 2002 Jul 5;16(10):1383-9.

PMID:
12131215
9.
10.
11.

Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients.

Badiou S, Thiebaut R, Aurillac-Lavignolle V, Dabis F, Laporte F, Cristol JP, Mercie P; Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA).

J Infect. 2008 Jul;57(1):47-54. doi: 10.1016/j.jinf.2008.05.007. Epub 2008 Jun 12.

PMID:
18554723
12.

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.

Tarr PE, Taffé P, Bleiber G, Furrer H, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vernazza P, Bernasconi E, Darioli R, Rickenbach M, Ledergerber B, Telenti A; Swiss HIV Cohort Study.

J Infect Dis. 2005 May 1;191(9):1419-26. Epub 2005 Mar 22. Erratum in: J Infect Dis. 2005 Jun 1;191(11):1997.

14.

A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease.

Adunsky A, Chesnin V, Davidson M, Gerber Y, Alexander K, Haratz D.

J Gerontol A Biol Sci Med Sci. 2002 Nov;57(11):M757-61.

PMID:
12403806
15.

Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype.

Shahmanesh M, Jaleel H, DeSilva Y, Ross JD, Caslake M, Cramb R.

Sex Transm Infect. 2001 Aug;77(4):283-6.

16.

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, Stoll M, Schmidt RE.

AIDS. 1999 Jul 9;13(10):F63-70.

PMID:
10416516
17.
18.

Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).

Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, Rozenbaum W.

Diabetes Metab. 1999 Sep;25(3):225-32.

PMID:
10499191
19.

Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients.

Tomazic J, Silic A, Karner P, Vidmar L, Maticic M, Poljak M, Ihan A, Janez A.

Wien Klin Wochenschr. 2004 Nov 30;116(21-22):755-9.

PMID:
15628647
20.

Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.

Koppel K, Bratt G, Schulman S, Bylund H, Sandström E.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):441-9.

PMID:
11981359

Supplemental Content

Support Center